396 related articles for article (PubMed ID: 34303670)
21. Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity.
Zarifa A; Lopez-Mattei J; Palaskas N; Iliescu C; Durand JB; Kim PY
Adv Exp Med Biol; 2020; 1244():277-285. PubMed ID: 32301022
[TBL] [Abstract][Full Text] [Related]
22. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
23. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors.
Reyes-Gibby CC; Qdaisat A; Ferrarotto R; Fadol A; Bischof JJ; Coyne CJ; Lipe DN; Hanna EY; Shete S; Abe JI; Yeung SJ
Head Neck; 2024 Mar; 46(3):627-635. PubMed ID: 38151809
[TBL] [Abstract][Full Text] [Related]
25. Routine assessment of cardiotoxicity in patients undergoing long-term immune checkpoint inhibitor therapy.
Tamura Y; Tamura Y; Yamada K; Taniguchi H; Iwasawa J; Yada H; Kawamura A
Heart Vessels; 2022 Nov; 37(11):1859-1865. PubMed ID: 35633369
[TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoint Inhibitor-Related Myocarditis: Recognition, Surveillance, and Management.
Kuhnly NM; Coviello J
Clin J Oncol Nurs; 2022 Feb; 26(1):54-60. PubMed ID: 35073300
[TBL] [Abstract][Full Text] [Related]
27. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.
Rubio-Infante N; Ramírez-Flores YA; Castillo EC; Lozano O; García-Rivas G; Torre-Amione G
Eur J Heart Fail; 2021 Oct; 23(10):1739-1747. PubMed ID: 34196077
[TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Inhibitor-Associated Myocarditis.
Ganatra S; Neilan TG
Oncologist; 2018 Aug; 23(8):879-886. PubMed ID: 29802219
[TBL] [Abstract][Full Text] [Related]
29. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
Agostinetto E; Eiger D; Lambertini M; Ceppi M; Bruzzone M; Pondé N; Plummer C; Awada AH; Santoro A; Piccart-Gebhart M; de Azambuja E
Eur J Cancer; 2021 May; 148():76-91. PubMed ID: 33740500
[TBL] [Abstract][Full Text] [Related]
30. Cardiotoxicities associated with immune checkpoint inhibitors.
Yang S; Asnani A
Curr Probl Cancer; 2018 Jul; 42(4):422-432. PubMed ID: 30173878
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitors and vasculitis.
Boland P; Heath J; Sandigursky S
Curr Opin Rheumatol; 2020 Jan; 32(1):53-56. PubMed ID: 31599800
[TBL] [Abstract][Full Text] [Related]
32. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system.
Michel L; Totzeck M; Lehmann L; Finke D
Herz; 2020 Nov; 45(7):645-651. PubMed ID: 32533218
[TBL] [Abstract][Full Text] [Related]
33. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis.
Won T; Kalinoski HM; Wood MK; Hughes DM; Jaime CM; Delgado P; Talor MV; Lasrado N; Reddy J; Čiháková D
Cell Rep; 2022 Nov; 41(6):111611. PubMed ID: 36351411
[TBL] [Abstract][Full Text] [Related]
34. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.
Peleg Hasson S; Salwen B; Sivan A; Shamai S; Geva R; Merimsky O; Raphael A; Shmilovich H; Moshkovits Y; Kapusta L; Rozenbaum Z; Wolf I; Laufer-Perl M
Clin Res Cardiol; 2021 Jan; 110(1):50-60. PubMed ID: 32296970
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management.
Eftekhar SP; Yazdanpanah N; Rezaei N
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1211-1228. PubMed ID: 34511008
[TBL] [Abstract][Full Text] [Related]
36. Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis.
Cau R; Solinas C; De Silva P; Lambertini M; Agostinetto E; Scartozzi M; Montisci R; Pontone G; Porcu M; Saba L
Int J Cancer; 2022 Dec; 151(11):1860-1873. PubMed ID: 35730658
[TBL] [Abstract][Full Text] [Related]
37. Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta-Analysis of Observational Studies and Randomized Controlled Trials.
Sharma A; Alexander G; Chu JH; Markopoulos A; Maloul G; Ayub MT; Fidler MJ; Okwuosa TM
J Am Heart Assoc; 2024 May; 13(10):e032620. PubMed ID: 38761070
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint inhibitor-related myocarditis: current understanding and potential diagnostic and therapeutic strategies.
Turker I; Johnson DB
Expert Opin Drug Saf; 2023; 22(10):909-919. PubMed ID: 37647330
[TBL] [Abstract][Full Text] [Related]
39. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do.
Zito C; Manganaro R; Ciappina G; Spagnolo CC; Racanelli V; Santarpia M; Silvestris N; Carerj S
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358830
[TBL] [Abstract][Full Text] [Related]
40. [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment].
Arangalage D; Pavon AG; Hugelshofer S; Desgraz B; Tzimas G; Delyon J; Muller O; Obeid M; Ribi C; Michielin O; Özdemir BC; Monney P
Rev Med Suisse; 2020 Jun; 16(696):1165-1168. PubMed ID: 32496706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]